BioPharma Credit increases size of share sale
BioPharma Credit, the UK closed-end investment fund that provides debt capital to the life sciences industry, has increased the size of a primary share offering by $50m to $200m
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts